multi-lin relief neuroblastoma look well beyond
current soc initi buy tp
y-mab clinic stage biotechnolog compani pivot trial
treatment primari neuroblastoma tumor naxitamab
subsequ metastas omburtamab compani plan submit
two bla around antibodi look activ current
naxitamab look like next-itamab nb patient receiv
benefit cr pr current front-lin regimen surgeri
radiat chemotherapi follow cours approv
mab unituxmab said mani patient also
relaps unituxin treatment regimen complex ae-laden
y-mab antibodi naxitamab look like excit option
provid benefit r/r nb patient also eventu becom
greatli improv option nb sever trial on-going
naxitamab beyond potenti pivot trial r/r nb
one ymab second drug appear extrem
activ area medicin lm real soc fda-agre
requir acceler approv realli bridg studi
new manufactur process data date make success seem like
put tiger sanctuari system oncolog continu
advanc particularli driven antibodi metastas
sanctuari site like continu increas preval
unfortun statist live longer see ymab expans
program wide rang metastat tumor
interest next leg stori
valuat valu y-mab base net incom
million discount price-to-earnings methodolog ep discount
rate risk includ standard drug develop risk orphan price
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
y-mab look unusu de-risk y-mab two lead therapeut licens
world-wide work progress mskcc compani took develop
two antibodi naxitamab human primari neuroblastoma
omburtamab murin metastas neuroblastoma mani
year clinic develop left believ littl doubt efficaci
fda seem agre mab breakthrough design
result prioriti review voucher prv mab approv
posit strong despit signific clinic opportun million ipo
expect y-mab good cash posit fact
reason chanc y-mab wont absolut need rais money said
stori lot potenti news flow potenti gener posit
clinic data chanc rais addit fund rel short term
seem high especi current market
naxitamab first clinic path look clear y-mab lead asset chimer
antibodi develop neuroblastoma nb compani licens antibodi
mskcc along two larg data set suggest orr around
r/r nb arm data compani agre plan fda
treat addit r/r nb patient goal demonstr orr
specif requir orr significantli better respons
week base agreement compani expect file first naxitamab
bla initi market look worth million million annual
real concern r/r nb heterogen diseas primari refractori
patient like never seen therapi demonstr much
higher orr secondari refractori patient like seen mani round
therapi result hit overal respons rate fda bless may
depend actual make-up patient pivot trial term trial
compani plan mix major risk trial seem ratio
two group patient
primari refractori patient probabl never got deep enough respons
receiv unituxin show orr
secondari refractori patient like relaps unituxin
show orr
naxitamab addit indic make sens addit r/r nb naxitamab
develop osteosarcoma line nb includ case
soc poor non-exist suggest efficaci like advanc overal
market naxitamab indic current clinic trial probabl approach
billion potenti pivot trial underway importantli
target indic lack approv soc public guidelin list
expect drive use true approv
orphan schmorphan naxitamab follow approv therapeut call
unituxin front line set unituxin clearli activ even clearli
difficult mab use y-mab run trial essenti unituxin indic nb
patient good respons induct chemo-radi surgeri import
distinct naxitamab much easier use safe administr period
minut rather pain hour requir deliv unituxin
potenti way bypass orphan protect addit naxitamab use without
immun stimul make regimen differ potenti second path
omburtamab clinic path look clear y-mab second antibodi test
trial involv children metastas origin nb tumor
term leptomeningioma well metastas tumor trial
gener efficaci profil look better current salvag soc nb
fda seem view program favor requir addit efficaci
data prior acceler approv agre upon plan run lm os trial full
approv approv purpos take earli look first patient bar
approv simpli demonstr current version omburtamab produc
convent method rather mice act similarli patient origin
antibodi compani expect file bla
thank good acronym short-term omburtamab pipelin involv two rare
desmoplast small round cell tumor dscrt sarcoma peritoneum
gener express target omburtamab neither
real soc trial indic underway dipg trial provid
confid y-mab broader target strategi
metastat diseas signific opportun ever advanc wave effect
anti-tumor mab target agent allow patient solid tumor live
longer flip side longer-liv patient experi
metastasi agent dont reach reach poorli medic
need clear throughout oncolog develop neratinib tucatinib
mbc base improv penetr one exampl area
intens interest
human mab dipc program treat gener metastat
tumor made impress progress eye compani develop
human version omburtamab new radio-nucleotide-link pair allow
central manufactur broader market compani also develop clinic
data pediatr metastat indic beyond nb indic feasibl
approach final antibodi readi ind submiss
attract target correct payload search tumor specif
target decad old safe say area make progress stake
clearli high target like uniqu b-cell fuel entir new arm
oncolog car-t tcr mani properti perfect-target
express high fraction tumor tissu problem
suggest buy pt effort simpli bind
doesnt much efficaci rise abil antibodi recruit immun
direct inject mab long term solut one area competit
concern y-mab overal approach direct inject approach
develop omburtamab surgeri rel common trial test
direct deliveri mab shown efficaci signal herceptin particular
howev multipl compani use transferrin receptor trick get
antibodi approach could eventu threaten y-mab
target seem inher appeal drag t-cell tumor said
develop therapeut complex
first mab tickl t-cell throughout patient result tendenc
trigger troublesom cytokin releas
second bifunct target strong tendenc get lost
lymphoid organ t-cell gather increas chanc never find
tumor
y-mab develop one mani approach seemingli clever avoid
problem antibodi scaffold potenti bind tumor twice via two fv
domain weakli bind one scfv domain first target
 gener myeloid target
manag work togeth mab develop mani year y-mab
spark came founder thoma gal whose person experi nb lm
result crusad bring mskcc antibodi children howev gal
didnt attempt go alon built compani experienc mab develop
princip genmab core expertis led clau moeller genmab
founder alreadi clear compani facil switch radioisotop
differ omburtamab target diseas expans franchis via
product human omburtamab user-friendli toxic payload
risk invest thesi
develop risk anyth pediatr probabl risk y-mab lead
therapeut intend pediatr market safeti bar approv
like elev compani report posit interact fda
receiv straightforward march order complet clinic packag
naxitamab multicent trial orr omburtamab convent
manufactur procedur said fda guidanc never bind
surpris activ could easili result delay
addit regulatori risk ad aspect risk naxitamab stori orphan
drug statu unituxin approv drug statu nb market could
protect shirley templ often comment everyon love
orphan case less sure naxitamab seem safer
effect unituxin use without concomit make actual indic
competit risk rel obviou target extrem therapeut
crowd oncolog expect y-mab could compani space
literatur full earli stage program target glycolipid seem earli
human develop made princip tumor certain nerv along
line high list attract oncolog target publish nci similarli
compani notic attract properti tumor target
potenti immunomodulatori agent macrogen particular broad
program fc enhanc antibodi bifunct antibodi
focus target
reimburs risk y-mab first product desper ultra-orphan
indic expect reach market high price situat
somewhat tenuou current climat drug type seem like attract
payor scrutini issu may strongest naxitamab drug may price
soc involv similar antibodi unituxin base naxitamab greatli
reduc hospit charg day less hospit worth
addit y-mab antibodi signific extent develop public
back mskcc prove ammunit cost cut argument y-mab certainli
isnt alon face risk worth watch
price risk mskcc employe work set y-mab place
board involv somewhat public controversi involv person
profit origin licens deal issu seem much intern mskcc
issu anyth els like minor distract howev current
climat muckrak happier issu clear
genmab team drive y-mab deeper pipelin
develop highli experienc field
develop includ bifunct develop crowd compani like
macrogen buy pt meru mru rate
work technic issu involv augment antibody-lik molecul y-
mab differenti focu rare pediatr cancer commerci valu
target like wide appreci result anyth y-mab could face
y-mab clinic pipelin timelin
y-mab stori princip two lead asset point naxitamab
neuroblastoma primari tumor omburtamab metastas nb
potenti pivot trial readout expect expect eye
progress trial
naxitamab addit indic event import includ trial broaden
indic naxitamab osteosarcoma second tumor also express
broaden nb indic salvag diseas later goal may
need modest clinic data nb desper indic naxitamab appear
activ toler current soc along line current
mab approv nb unituxin orphan drug statu grant
expect protect howev naxitamab safer avonex got
around betaseron orphan protect deliv combin
make regimen differ
omburtamab addit indic y-mab second antibodi sever trial
ultra-orphan tumor small indic expect omburtamab
expens model per cours progress like valuabl
earlier program good think y-mab would pretti decent stori without
two frontlin mab overal approach treat contain metastas
solid tumor attract patient similar price point seem well
way human mab complet linker radio-nucleotid chosen
program label data omburtamab target patient could realli drive
interest program final bifunct mab pipelin driven
experienc antibodi jock everyth look good overal bifunct field
seem verg break doldrum domin posit pediatr
side market could anoth nice chapter y-mab stori
y-mab financi model assumpt
financi model y-mab base assumpt number patient
type address tumor well final cost two y-mab
antibodi compani estim shown exhibit larg adopt
number base public estim seen
price conserv use naxitamab base expect
broadli appreci superior approv antibodi use
cog mab initi base small scale product
may overli conserv
omburtamab adopt higher price base smaller market
vastli improv os current soc fact mab radiolabel base
rel complex manufactur involv three site three countri adopt
higher cog omburtamab
exhibit price sensit analysi
price earn valuationtarget incom multipl period
thought nb market current sale unituxin commerci name
dinutuximab million annual number probabl
fraction naxitamab might gener goe well firstli unituxin use
mskcc hospit still treat case secondli unituxin
extrem difficult take current dropout rate final unituxin
price full treatment cycl total cost use
antibodi also involv approxim day reimburs hospit base
histori safeti efficaci naxitamab expect commerci use mskcc
lower drop-out rate least price premium unituxin target market
million
r/r nb market neuroblastoma patient receiv treatment
 approxim achiev long-term evf remain patient
repres initi on-label popul naxitamab r/r nb
salvag market y-mab trial on-going salvag patient fail
prior treatment high risk patient essenti repres r/r
failur expect patient might get naxitamab
least twice on-going trial show sign
omburtamab price market use higher price omburtamab
base rariti lm extrem compel efficaci seen date trial
fact molecul radiolabel
ex-u assumpt outsid assum market size naxitamab
 approv year delay price haircut
number unknown patient model explicitli rather start
 patient treat add one ex-u patient equival
 patient treat previou year
 manag given guidanc post ipo cash runway
assum spend base initi expect
million ipo manag guid cash guidanc equat cash burn
million million
sg size y-mab sale forc expect grow patient
longer treat singl center still expect remain small estim
peopl overal
sale estim consensu naxitamab sale estim naxitamab per patient probabl success weight revenu market revenu patient treat us patient treat us patient ttreat row relapsed/ refractori neuroblastoma us row case neuroblastoma r/ r/r patient nb patient treat naxitamab nb patient treat naxitamab neuroblastoma us row case neuroblastoma high risk high risk patient nb patient treat naxitamab nb patient treat naxitamab osteosarcoma us case pediatr ya patient patient treat
mskcc relationship base amount work perform mskcc
naxitamab omburtamab deal memori look favor y-mab
fair time compani form unituxin verg
approv unclear commerci opportun second
antibodi y-mab initi went r/r nb market superior properti
naxitamab rel unituxin look pretti obviou
base partial improv fortun mskcc deal result mid high singl
digit royalti sale mileston total million also
sponsor research agreement mskcc unlik materi
naxitamab omburtamab patent protect naxitamab omburtamab
older antibodi signific method use protect beyond
sale estim sale estim omburtamab per patient success weight revenu market revenu patient treated- pediatr nb lm ww pediatr case neuroblastoma cns/ cns/ lm treatabl patient patient patient treat
naxitamab lead program r/r nb bla expect
y-mab initi focu neuroblastoma nb diseas princip affect children
high probabl take bad cours tumor resolv spontan
respond front-lin therapi y-mab develop naxitamab treat primari
nb tumor gener metastat diagnosi well omburtamab treat
nb metastas occur term leptomening metastas
nb antibodi seem promis could consid lead program
cover naxitamab first y-mab chimer mostli human mab
mskcc data trove y-mab took develop naxitamab larg
amount clinic data gener chimer antibodi even larger
amount fulli murin antibodi target specif see exhibit
key trial mskcc studi treat r/r nb patient dose
rang portion expans cohort
exhibit chimera mice men
first import clinic trial naxitamab call first data
naxitamab dose rang portion trial section trial defin
go-forward dose despit signific dose switch within patient real dose
respons observ probabl uncommon academ ultra-orphan studi
efficaci naxitamab trial left littl doubt orr primari
refract patient orr secondari refract patient see exhibit
consid efficaci number import addit aspect trial
first trial combin naxitamab gm-csf innat immun system
activ includ adapt immun system activ
differ probabl help improv safeti profil rel approv
high dose naxitamab deliv patient much dose
approv antibodi unituxin
patient trail older neg risk factor nb mean age
nearli seven year age three year sinc diagnosi
perhap importantli treat previous
antibodi latter issu import mani patient pivot trial
like treat unituxin
safeti also impress trial reach patient safe
treat mg/kg per cycl world antibodi oncolog better
final dose naxitamab dose given safe
either earlier murin version naxitamab unituxin approv mab
overal trial patient experienc treatment-rel sae none fatal
one patient develop anaphylact reaction cycl withdrew treatment
anoth patient withdrew develop grade angioedema immedi
complet second cycl frequent observ teae pain
hypotens fever pruritu urticaria
exhibit result dose-find cohort mskcc trial
issu trial one import aspect y-mab stori current
depend academ data mskcc likelihood trial run
slightli relax requir possibl result bia first trial may
exampl patient includ analysi efficaci
patient exclud final analysi base evid diseas similarli
patient evalu diseas seven patient progress diseas pd
studi entri consid final analysi overal modif
seem accept worth note probabl explain fda
requir run pivot trial multipl site beyond mskcc
phase portion studi good data
base dose rang part trial y-mab began discuss
fda pivot design addit patient treat defin
go-forward dose expans arm studi singl arm
design assess anti-nb activ naxitamab gm-csf patient
present lesion could object measur and/or monitor i-
mibg scan patient deem measur diseas addit goal
appli quantit rt-pcr test hypothesi minim residu diseas
bone bm prognost impact outcom look biomark success earli
treatment
may top-line result first patient phase studi
present continu show respons rate near seen dose
escal part studi primari refractori patient respond
secondari refractori patient respond orr much
lower secondari refractori patient reflect prior treatment essenti
patient antibodi
trial also treat third group patient assess impact naxitamab
gm-csf patient second good respons therapi mainten
second cr vgpr group ef suggest addit
line nb therapi may employ naxitamab
pivot trial studi y-mab fda agre upon singl arm
open-label trial test naxitamab produc cgmp manufactur
treat patient outsid mskcc total site expect trial protocol
studi expect enrol patient y-mab level agreement
patient profil studi similar patient trial
trial could pool fda regulatori purpos primari endpoint trial
orr gener case relaps trial fda guid respons
week durat along accept safeti profil secondari
object includ safeti durat respons dor os year pk profil
format haha immun reaction naxitamab
safeti data addit studi y-mab also run studi
phase studi naxitamab without gm-csf octob patient
enrol studi total studi start naxitamab shown
safe use gm-csf becom larg unimport beyond addit
patient experi provid
fli ointment octob fda issu partial clinic hold ind
studi y-mab partial clinic hold base propos
accept criterion cdc assay
consid wide provid suffici control paramet
potenti relat pain side effect antibodi y-mab submit
respons fda march met fda april
partial clinic hold remov june issu seem resolv
worth note antibodi naxitamab unituxin use young children
without pain side effect surpris type probabl
common type program
naxitamab studi nb
front line nb public key step expect naxitamab also test
front-lin nb studi essenti posit unituxin sit
trial essenti design make publish data avail cover use
naxitamab nb time approv nb
date patient enrol treat naxitamab/gm-csf
immunotherapi along isotretinoin without goal consolid
remiss experienc initi chemo-surgery-radi treatment
standard high risk nb patient
trial enrol patient high risk nb slightli modern definit
design captur neg prognost valu amplifi mycn nb patient
mycn-amplifi stage age
mycn-nonamplifi stage patient month age patient
must first cr/vgpr
salvag high risk patient studi make clear secondari relaps
patient harder treat full induct therapi probabl
cours unituxin achiev truli durabl respons tri improv
orr seen studi y-mab treat patient combin
naxitamab plu chemotherapi studi singl arm high-risk r/r nb
patient soft tissu diseas date patient treat naxitamab
combin irinotecan temozolomid sargramostim
naxitamab treatment relaps osteosarcoma
sever tumor type express glycolipid sialo-gangliosid base
exot sugar y-mab chosen osteosarcoma first test
osteosarcoma anoth desper indic treatment option expect
public posit clinic data overal safeti profil antibodi
begin drive use reimburs model modest use
straightforward lm antigen express mani osteosarcoma
tumor howev densiti express high tumor probabl
less immuno-respons nb program probabl littl experiment
nb howev clinic need osteosarcoma sarcoma high clear
efficaci could valuabl refer osteosarcoma occur new
patient annual eu current treatment involv
chemotherapi surgeri radiat aggress treatment result long term
remiss patient metastat diagnosi
patient relaps diagnos metastat diseas prognosi
good salvag therapi poor essenti os without addit
success surgic recurr success surgeri patient
begin recur diseas site metastat diseas treat surgic
gener recur elsewher role naxitamab patient address
microscop minim residu diseas remain even success surgeri
break cycl reoccurr
exhibit osteosarcoma also express antigen
naxitamab current r/r osteosarcoma trial studi treatment
patient undergon success surgeri buy probabl residu
microscop diseas last report octob patient enrol
expect y-mab eschew round number trial also treat patient gm-
csf power demonstr ef level activ would
significantli better seen current salvag therapi trial
stratifi base express believ enrich type may make
sens subsequ trial
background neuroblastoma treatment
neuroblastoma nb one common pediatr tumor account
cancer death children nb often metastat time diagnosi
patient characterist principl basi defin nb high risk
late supplement molecular marker nb incid
patient anoth eu nb form immatur cell
nervou system base complex way cell move around
develop tumor often seen outsid nervou system adren
gland abdomen chest addit tumor also seen spinal cord nb
heterogen cancer lower risk patient spontan cure diseas
occur earli enough develop gener month age spontan
cure also suggest nb highli immunogen diseas describ nake
antibodi unusu effect contrast high-risk neuroblastoma defin
metastat diseas diagnosi account case remain poorli
control surviv rate
exhibit unusu strong treatment effect nake antibodi
nb patient also place differ risk group low intermedi high
base stage prognost factor high-risk nb defin mycn
amplifi stage patient age mycn non-amplifi stage
patient month age
neuroblastoma treatment treatment high-risk neuroblastoma includ induct
chemotherapi surgeri radiat therapi myeloabl chemotherapi lead
auto-sct patient t-cell intens treatment signific long term
consequ children surviv diseas suffer chronic health condit
includ delay growth hear loss poor renal function secondari malign
induct therapi patient minim residu diseas treat
isotretinoin acid reactiv lipid decreas prolifer
induc differenti neuroblastoma cell use isotretinoin base larg
double-random studi publish nejm studi enrol almost
patient show benefit bone marrow transplant first random
exhibit upper schemat isotretinoin second random overal result
ef rate three year first random significantli better
patient assign transplant vs patient
assign receiv continu chemotherapi vs
ef three year second random significantli better
patient assign receiv isotretinoin vs patient
assign receiv therapi vs
addit two treatment addit exampl patient receiv
isotretinoin sct longest median ef patient receiv neither
treatment shortest median ef exhibit lower graph
exhibit complex trial establish bmt isotretinoin soc
immunotherapi introduc next phase nb therapeut develop focus
find anti-nb antibodi sens nb patient fortun
somewhat obscur natur nb tumor made search tumor specif target
product sever candid found includ gangliosid call
sever antibodi develop
promis nb target membran lipid cover complex sugar
chain express fetu earli develop express princip
peripher neuron central nervou system skin melanocyt
biolog remain somewhat unclear relev y-mab stori
express high percentag neuroblastoma tumor high
percentag individu neuroblastoma cell within tumor may
activ role tumor growth express nsclc osteosarcoma seem
correl enhanc tumor prolifer invas also found
sometim lower level number tumor type includ melanoma soft
tissu sarcoma osteosarcoma small cell lung cancer sclc
pain truth express adult larg confin peripher
neuron specif target posit fight tumor local
make use antibodi extrem pain pain step believ
actual bind antibodi neuron stabli bound antibodi
less pain describ patient treat unituxin endur extrem pain
approxim patient contribut factor includ lower affin
slow dose requir unituxin make dose window unituxin last
treatment companion also caus problem antibodi respons
solid tumor larg ineffect hand except rule includ
herceptin antibodi bind inhibit growth factor receptor known
driver specif tumor growth partli overcom situat
antibodi develop combin gm-csf stimul nk cell
macrophag innat immun system power stimul t-cell
adapt immun system co-develop nb appear data driven
base earli experiment trial although addit dont aid
mab fight tumor rituxan exampl howev complic issu safeti
particular cytokin caus extrem side effect although use
monotherapi certain cancer requir extrem caution exampl
heyday rcc drug subset hospit would use drug gener
one patient time due special staf requir
road unituxin antibodi activ test nb
year case limit factor acut pain result
express peripher nerv fiber inabl antibodi treat bulki
tumor despit issu sever four antibodi realli mous
human version two antibodi test
clinic trial earli data gener mous antibodi thing
look promis antibodi modifi human chimer version
first step human introduc human fc domain exhibit
trial progress dinutuximab commerci unituxin chimer anti-
monoclon antibodi approv combin granulocyte-macrophag
coloni stimul factor gm-csf isotretinoin acid ra
mainten treatment pediatr patient high-risk neuroblastoma
achiev least partial respons therapi gener chemotherapi surgeri
phase trial dinutuximab test patient high-risk nb essenti
metastat respond induct therapi stem-cel transplant
randomli assign six cycl isotretinoin alon six cycl isotretinoin
five concomit cycl unituxin combin altern gm-csf
unituxin treatment superior standard therapi regard year ef
vs os vs base trial
unituxin approv black box warn shown exhibit
take aim unituxin safeti featur unituxin leav room improv
naxitamab develop focus issu differ
antibodi regimen potenti import unituxin orphan drug
statu nb naxitamab may need either advantag get on-label use although
label may crucial differ antibodi includ
higher bind affin naxitamab may reduc overal pain
treatment featur need proven clinic trial longer on-
time naxitamab result fewer antibody-to-nerv bind event pain
consid relat process
much shorter infus period minut rather hour
durat pain much shorter treatment given
outpati set avoid day hospit cost
lack co-administr cytokin design increas
destruct antibodi coat tumor cell gm-csf power t-
cell stimul also result side effect associ
fewer fusion site reaction allow rapid deliveri muck larger
quantiti antibodi featur may result better efficaci
need proven expect much higher peak
level antibodi allow signific level complement-depend cell
cytotox cdcc naxitamab addit antibody-depend cell
cytotox adcc expect antibodi
exhibit naxitamab attract properti rel unituxin
pipelin attract target gone unnot
larg number research preclin effort on-going y-mab like
pursu vaccin strategi along naxitamab program overal
highli immunogen natur nb suggest immun system amplif may work well
antibodi expect progress like come gener
area howev none molecul current formal clinic trial
furthermor lead candid y-mab bifunct platform includ
bifunct antibodi expect antibodi pro y-mab like
thick effort
exhibit focu mani development effort treat nb
omburtamab leptomening metastas neuroblastoma
nb isnt bad enough diseas increas tendenc reoccur
membran surround brain term leptomening metastas y-mab
second therapeut omburtamab iodine-radiolabel murin mouse-deriv
antibodi target antigen found neuroblastoma tumor
result antigen found primari tumor metastas neuroblastoma
tumor also contain antigen antigen otherwis absent
develop omburtamab also benefit consider develop
mskcc prior format y-mab case clinic trial alreadi
complet left littl doubt antibodi efficaci util treat
lm left y-mab modern develop omburtamab
carri bridg studi demonstr make antibodi via convent
method rather mice done mskcc chang
distribut properti patient brain studi underway bla
omburtamab expect
unlik naxitamab omburtamab deliv directli patient tissu via
ommaya reservoir exhibit approach requir tumor separ
patient system circul blood brain barrier structur antibodi wont
gener cross exclus isnt absolut anti-alzheim diseas ad
antibodi aducanumab deliv system target a-beta plaqu
brain howev estim suggest deliv
aducanumab actual make brain oncolog indic
antibodi better
exhibit omburtamab deliv directli
given somewhat complex deliveri omburtamab efficaci bar develop
probabl pretti high shown exhibit mskcc trial suggest efficaci
omburtamab better anyth test
compar data exhibit patient treat ln mskcc prior
start develop omburtamab result fairli old mo
month prior howev soc lm chang appreci mani
year similar soc data recent collect lm patient larg
retrospect german studi treat median os month final
publish research repres patient treat show
median os month
clinic pipelin omburtamab beyond lm
y-mab also develop omburtamab two addit indic also involv
direct deliveri radiolabel omburtamab express tumor two
indic
diffus intrins pontin glioma dipg brainstem diseas affect
children annual suggest children eu
tumor posit tumor diffus
invad health tissu critic region brain pon respons
breath surgeri gener imposs leav palli radiat
major treatment surviv gener less one year
desmoplast small round cell tumor dsrct tumor gener occur
tissu line insid abdomen pelvi peritonium
aggress soft tissu tumor essenti sarcoma tumor
type express popul estim patient
 annual annual eu major brainstem tumor
real treatment standard care
overview dipg dsrct
dipg tricki diseas treat dipg typic affect children age
five nine year old common pediatr brainstem tumor grow
extrem critic area brain respons respir conscious
area sever import cranial nerv result omburtamab modifi
contain iodin rather iodin new conjug allow precis
dosimetri dose consid crucial import region brain interim
data on-going trial deliv omburtamab via convect enhanc deliveri
ced introduc make mab diffus inject site present
suggest approach work consist view i-
omburtamab receiv rpdd fda treatment dipg
trial perform stereotact placement small calib infus cannula
tumor follow slow infus ced i-omburtamab progress
sinc interim look octob dipg patient expect
treat i-omburtamab y-mab indic trial like
expand addit site y-mab plan trial serv basi sbla
dsrct gut shot omburtamab dsrct aggress form sarcoma
connect tissu cancer primarili affect children young adult
common male form small round cancer cell surround scar-lik tissu
often found peritoneum tissu line insid abdomen
pelvi patient present abdomin pelvic tumor subsequ
metastas distant lymph node bone marrow lung patient typic
manag aggress intraperiton chemotherapi ip enclos caviti allow
aggress dose maxim surgic de-bulk whole abdomin radiat
often stem cell rescu despit aggress treatment five-year os rate
less patient almost invari relaps
studi dose less critic y-mab use omburtamab
current i-omburtamab evalu on-going clinic studi studi
treatment dsrct tumor peritoneum trial
enrol patient sinc base result y-mab expect wait
approv omburtamab lm discuss fda possibl
sbla periton use antibodi
metastasi marker
brain metastas like heart diseas oncolog prior modern therapeut
one use live long enough get era modern oncolog mani
patient live longer often much longer due highli effect mab bc
target agent nsclc unfortun mab major target agent
dont cross blood brain barrier effici result tumor cell find
way often shield effect therapeut final stimulu
treatment tumor imag techniqu improv point
metastas detect earlier
leptomening metastasi lm seen nb patient tumor form
line migrat tumor
tumor occur annual littl soc beyond palli radiat lm current occur
patient advanc solid tumor common solid
malign lead leptomening metastasi adenocarcinoma breast
lung along melanoma matter tumor give rise
lm prognosi poor median overal surviv diagnosi month
data support gener use y-mab alreadi gener signific data
support idea metathes tumor nb treat
omburtamab mscc studi treat lm nb patient
fact gener studi treat patient metastas
tumor patient serv basi y-mab decis target
reoccurr broadli summari data shown exhibit
exhibit omburtamab data non-nb-deriv metastas
target much know come anoth mab
powerhous macrogen perhap experienc compani area
tune mab enhanc function particularli bind multipl ligand
seen exhibit seen mani tumor type rare healthi tissu
exhibit express mani tumor type
antibodi mass mass omburtamab look like signific
advanc children lm y-mab gener data support
antibodi use gener metastas express marker howev
omburtamab complex manufactur use base high energi short half-lif
iodin radionucleotid result y-mab work improv
mab radionucleotid pair catchi monik lu-omburtamab-dtpa
beta radiat similar beta radiat emit radioact
iodin alreadi demonstr efficaci cns/lm nb conjug
omburtamab
although tongue-twist name therapeut sever advantag
origin omburtamab human antibodi conjug
metal-chel bind moieti dtpa result antibodi
less subject infus site reaction stabl enough ship
hospit administ single-step push dose administr patient
use ommaya reservoir similar administr i-omburtamab
vaccin program might ideal indic
beyond two lead antibodi rel straightforward develop path
technolog platform design next gener antibodi y-mab acquir
probabl plan develop neuroblastoma vaccin vaccin expect
come mskcc initi licens mabvax subsequ sub-licens
vaccin y-mab vaccin strong t-cell activ conjug
shown safe melanoma patient also gener antibodi
respons patient trial publish mabvax vaccin
grant orphan drug design treatment neuroblastoma return
mabvax get million mileston up-front payment along
share prioriti review voucher might result develop vaccin
clinic trial progress vaccin mskcc treat children
r/r nb studi achiev respons requir approv
naxitamab set mainten set make sens us children
opt extens studi like serv reason control arm
uniqu properti nb make us believ program
puncher chanc success pluss minus summar
skeptic program stem mani concern
seem plagu cancer vaccin space gener
antigen use therapeut essenti self-antigen mount
immun system respons self-antigen complex complex
direct result strong pre-select t-cell self-react
occur
said sign nb unusu immunogen cancer
immun system may need tini push get go addit antibodi
unusu activ nb comment base abil mani
children spontan clear nb tumor month
tumor-erad activ antibodi phase diseas
research pipelin bi-mab platform
thoma gal start y-mab brought team experi antibodi jockey
genmab see evid team antibodi experi rapid
develop human omburtamab switch radio-isotop
throughout omburtamab program match requir differ diseas
locat potenti side effect also clear team quit interest
bifunct antibodi space unsurpris interest given genmab spun
medarex one pioneer bifunct antibodi review y-mab
program modest detail think solv known complex
develop bifunct mab bi-mab uniqu way forese futur
expect investor focu two nb-relat bla remain signific
unmet need oncolog se may hear program long
exhibit natur antibodi bind two copi one antigen
lead program y-mab indic bifunct antibodi
program initi target two differ applic
 bi-mab slate clinic like involv two trial
trial start dose-rang cohort standard escal scheme worth
rememb dose-find period trial bi-mab bind
lengthi safeti reason describ first plan trial pediatr cancer
trial like sclc express second basket trial
express tumor adult patient
second program still research phase target wide express
antigen myeloid cell target pass favor mani
compani kite/gilead merg rate
compani ziop/xon rate await detail y-mab plan
reason choos antigen
manag indic program aim provid safer mylotarg-lik
antibodi probabl pediatr acut lymphoblast leukemia mylotarg
antibody-drug-conjug tough antibodi use withdrawn
safeti reason result expect bar better low addit
signific use mylotarg despit safeti concern medic need high
overal program look like anoth interest program y-mab
bi-mab challeng tickl t-cell find tumor idea drag
t-cell tumor inher attract unfortun yenta-mab therapeut
capabl enforc uncomfort meet difficult design
development complex stem gener issu lot t-
cell nowher near tumor indiscrimin activ
t-cell result stormi cytokin mess addit lot t-cell human
antibodi affin via bind ubiquit
receptor like go lymph tissu never leav t-cell matur huge
antibody-focus compani solv problem reduc affin
bi-mab move away molecul bind
gener use framework xmab framework dart
platform abl bind tumor tightli coax
contain t-cell proxim
safeti signal safeti major concern develop antibodi bind
issu spuriou activ t-cell pure theoret
sever high profil clinic hold space exampl johnson johnson
 suspend phase studi place clinic hold
macrogen seemingli stop develop bi-mab initi
recent rate report clinic hold trial
involv hold involv dlbcl trial trial
report base sae one event fatal trial
case inform avail bind affin suspect molecul
flexibl linear construct two copi bind domain two copi
bind domain exhibit type construct high avid t-cell
probabl increas abil caus long run abil gener
power immun respons goal studi mimic car-t respons
clearli complex goal signific learn curv
exhibit structur allow tight t-cell interact activ
bifunct histori much origin interest bi-mab bring immun cell
site tumor idea one antigen bind site
antibodi bind tumor antigen bind site bound immun cell
major problem approach natur antibodi construct b-
cell two copi uniqu heavi chain two copi uniqu light chain
true given person make million differ heavi chain
combin million light chain matur b-cell make singl heavi
chain singl light chain combin form antibodi two copi
antigen bind site exhibit word antibodi divers
protect us mani invad come divers repertoir b-cell
mani approach solv bi-mab problem probabl
posit neg exhibit good exampl bite platform
rate use develop blincyto approv bi-mab
approv oncolog bite small show high solid tumor lymphoid mass
permeabl seem posit howev small size lack fc domain
result short half-lif neg necessit continu dose similarli
genmab rate duobodi platform creat fulli human antibodi
clinic meaning pk profil requir complex purif process
describ advanc bi-mab framework along approach
exhibit bifunct antibodi bi-mab come mani flavor
antibodi produc re-shuffl vitro harken
back first bi-mab
clever design rumor complex produc
market hemophilia
one fab one scab one true heavi chain allow convent
promis io
market exampl oncolog blinatumomab
nhl rapid clearanc result continu
solv heavi chain problem knob hole design gener b-cell
express multipl antibodi heavi chain light chain
rel straightforward exercis molecular biolog problem express
two copi lead larg number differ matur antibodi cell
natur heavi chain light chain pair indiscrimin exampl two
copi chain exampl lead
sever other manufactur standpoint kind disast
first solut problem construct antibodi heavi chain
unabl form homo-dim everi antibodi structur
technolog call knob hole rel intuit exhibit top left event
singl light chain express strategi produc singl bifunct
antibodi issu common light chain might work bind differ
antigen like tumor target
solv light chain problem crossmab xmab solut roch
tackl light chain problem differ way roch essenti
swap sequenc one light chain one heavi chain result
structur isnt truli antibodi act like one similarli use one
true heavi chain second heavi chain fragment end singl chain antibodi
detail illustr exhibit import thing structur
solv uniqu bifunct structur problem
exampl bifunct antibodi framework still look winner
y-mab approach y-mab solut differ gener
essenti normal antibodi bind uniqu antigen y-mab ad
true antibodi solv purpos provid singl product b-cell
bind two distinct antigen unlik crossmab xmab y-mab structur
two bind site howev tuck second site armpit
antibodi structur result steric hindranc allow one recognit
domain bind singl t-cell contrast normal antibodi arm y-mab
structur abl bind tumor antigen result shown
work field bi-mab structur
bind tumor tightli two separ antibodi arm
bind lightli one place one armpit domain
produc uniqu bi-funct product t-cell
overal expect y-mab continu work pediatr indic bi-mab
two lead program attract investor interest gener space
crowd y-mab reason approach experienc team addit
focu pediatr oncolog seem rel uniqu
manag new compani old compani
manag work togeth mab develop mani year y-
mab spark came founder thoma gal whose person experi nb
lm result crusad bring mskcc antibodi children howev
gal didnt attempt go alon built compani experienc mab expert
princip genmab core expertis led clau moller genmab
founder alreadi clear compani facil switch radioisotop
differ omburtamab target diseas expans franchis via
product human omburtamab user-friendli toxic payload
y-mab incom statement prob good margin develop administr administr profit margin incom tax redeem convert prefer share share
y-mab inc balanc hold balanc current stockhold liabil stockhold
btig cover compani mention report
appendix analyst certif import disclosur
